1-7 of 7
Rose Wangen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Study of FT538 + Daratumumab for Treatment of r/r AML

Joseph E. Maakaron, Cassie Seichter, Rose Wangen, Andrea Hoeschen, Deepa Kolaseri Krishnadas, Kateryna Kent, Ryan Shanley, Daniel O'Leary, Najla H El Jurdi, Shernan G. Holtan, Brian Betts, Mark Juckett, Jeffrey S Miller
Journal: Blood
Blood (2023) 142 (Supplement 1): 4842.
https://doi.org/10.1182/blood-2023-189132
Published: 2023
Journal Articles

Gda-201, a Novel Metabolically Enhanced Allogeneic Natural Killer (NK) Cell Product Yields High Remission Rates in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (NHL): 2-Year Survival and Correlation with Cytokine IL7

Veronika Bachanova, Joseph E. Maakaron, Frank Cichocki, David H. McKenna, Qing Cao, Todd E. DeFor, Murali Janakiram, Rose Wangen, Zuzan Cayci, Bartosz Grzywacz, Ronit Simantov, Tracey Lodie, Jeffrey S. Miller
Journal: Blood
Blood (2021) 138 (Supplement 1): 3854.
https://doi.org/10.1182/blood-2021-149989
Published: 2021
Journal Articles

Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer (NK) Cells in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma

Veronika Bachanova, MD PhD, Joseph Maakaron, MD, David H. McKenna, MD, Qing Cao, MS, Todd E. DeFor, MS, Fiona He, MD, Murali Janakiram, MD, Rose Wangen, Zuzan Cayci, MD, Bartosz Grzywacz, MD, Ronit Simantov, MD, Tracey Lodie, PhD, Jeffrey S. Miller, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 6.
https://doi.org/10.1182/blood-2020-142419
Published: 2020
Journal Articles

GTB-3550 TriKE™ for the Treatment of High-Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML) Safely Drives Natural Killer (NK) Cell Proliferation At Initial Dose Cohorts

Erica D. Warlick, MD, Daniel J. Weisdorf, MD, Daniel A. Vallera, PhD, Rose Wangen, Dixie Lewis, RN,BA, JoAnn Knox, Martin Schroeder, Martin Felices, PhD, Jeffrey S. Miller, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 7–8.
https://doi.org/10.1182/blood-2020-136398
Published: 2020
Journal Articles

Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer Cells (NAM-NK) in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM)

Veronika Bachanova, MD PhD, David H. McKenna, MD, Xianghua Luo, PhD, Todd E. DeFor, MS, Fiona He, MD, Murali Janakiram, MD MS, Erica D. Warlick, MD, Rose Wangen, Zuzan Cayci, MD, Bartosz Grzywacz, MD, Guy Brachya, PhD, Tony Peled, MSc, Jeffrey S. Miller, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 777.
https://doi.org/10.1182/blood-2019-130476
Published: 2019
Journal Articles

Adaptive NK Cell Expansion Is Associated with Reduced Relapse of Lymphoid Malignancies after Autologous Hematopoietic Cell Transplant

Rohtesh S. Mehta, MD MPH, MS, Rose Wangen, Frank Cichocki, PhD, Martin Felices, PhD, Xianghua Luo, PhD, Daniel J. Weisdorf, MD, Michael R. Verneris, MD, Jeffrey S. Miller, MD, Sarah Cooley, MD
Journal: Blood
Blood (2016) 128 (22): 515.
https://doi.org/10.1182/blood.V128.22.515.515
Published: 2016
Journal Articles

Clonal Expansion of Adaptive NK Cells and NKG2C + CD57 + KIR-Expressing T Cells from Sibling, but Not Umbilical Cord Blood, Grafts Is Induced By Recipient Latent CMV and Is Associated with Protection Against CMV Reactivation

Zachary B. Davis, PhD, Frank Cichocki, PhD, Martin Felices, PhD, Rose Wangen, Todd E. DeFor, MS, Sarah A. Cooley, MD MS, Yenan T. Bryceson, PhD, Don J. Diamond, PhD, Claudio Brunstein, MD, Bruce R. Blazar, MD, John E. Wagner, MD, Daniel J. Weisdorf, MD, Amir Horowitz, Lisbeth A Guethlein, Peter Parham, PhD, Michael R. Verneris, MD, Jeffrey S. Miller, MD
Journal: Blood
Blood (2014) 124 (21): 181.
https://doi.org/10.1182/blood.V124.21.181.181
Published: 2014